Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ipratropium (ausschl. Dafo. LOV), ATC R03BB01 für die Zeit 01.04.26 - 31.03.28 (zzgl. V.-Option 1x12 Monate)
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ipratropium (ausschl. Dafo”. Bids close on 5 February 2029.
The work
Framework discount agreement for Ipratropium (ATC R03BB01) for DAK-Gesundheit from 01.04.2026 to 31.03.2028.
- non-exclusive discount agreement
- ATC R03BB01
- LOV formulation only
Key facts
- Contract period
- 01.04.2026 - 31.03.2028 (with 1x12 month extension option)
- Evaluation
- Not a formal procurement, but a framework agreement
What it takes to qualify
Worth a closer look
- § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be borne by the statutory health insurance funds.
- The DAK-Gesundheit intends to conclude medicinal product discount agreements with as many interested pharmaceutical companies as possible until new medicinal product discount agreements come into force.
- The tender document is for a non-exclusive discount agreement, not a formal procurement procedure.
- The selection criteria are 'See application letter'.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Angebotsschreibensubmitted via email
- Anerkennung der vertraglichen Maßgaben der DAK-Gesundheitsubmitted via email
- Anlage 1 zum Vertragsubmitted via email
- Anlage 2 zum Vertragsubmitted as Excel file via email